J1921 HCPCS code: Injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg
J1921 is the HCPCS Level II code for injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg. In 2024 Medicare paid an average of $1.18 per service for J1921 across 113 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. In 2024, about 8 clinicians billed Medicare for J1921 for 11 beneficiaries.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2023-07-01 |
| Last action effective | 2024-07-01 |
Who bills J1921 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 8 |
| Medicare beneficiaries | 11 |
| States with claims | 0 |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J1921, 2024–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2024 | 113 | 11 | $1.44 | $1.18 |
What changed for J1921
- 2023-07-01: J1921 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J1921?
J1921 is the HCPCS Level II code for injection, labetalol hydrochloride (hikma), not therapeutically equivalent to j1920, 5 mg. Short descriptor: "Inj labetalol hcl hikma, 5mg".
How much does Medicare pay for J1921?
In 2024, the average Medicare payment was $1.18 per service (average allowed $1.44).
Does Medicare cover J1921?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related J19 codes
- J1920 — Injection, labetalol hydrochloride, 5 mg
- J1930 — Injection, lanreotide, 1 mg
- J1931 — Injection, laronidase, 0.1 mg
- J1932 — Injection, lanreotide, (cipla), 1 mg
- J1938 — Injection, furosemide, 1 mg
- J1939 — Injection, bumetanide, 0.5 mg
- J1940 — Injection, furosemide, up to 20 mg
- J1941 — Injection, furosemide (furoscix), 20 mg
- J1942 — Injection, aripiprazole lauroxil, 1 mg
- J1943 — Injection, aripiprazole lauroxil, (aristada initio), 1 mg
- J1944 — Injection, aripiprazole lauroxil, (aristada), 1 mg
- J1945 — Injection, lepirudin, 50 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J1921
- Watch J1921 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J1921
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.